To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

House Bill

H.R. 1492

119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

In Committee

Introduced:May 19, 2025

Primary Sponsor

Gregory F. Murphy

Representative

Republican

NC-3

Cosponsors

26

Quick Stats

Policy Area

Economics and Public Finance

Summary

This bill amends the Social Security Act to equalize the negotiation period between small-molecule drugs and biologics under the Drug Price Negotiation Program. Currently, small-molecule drugs and biologics may have different timelines before becoming eligible for Medicare price negotiation. The bill would align these periods to ensure consistent treatment regardless of drug type. This addresses concerns that the different timelines created unequal incentives for pharmaceutical development between drug categories.

Latest Action

Referred to the House Committee on the Budget.

SponsorGregory F. Murphy (R-NC)

Introduced5/19/2025

StatusReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

This bill amends the Social Security Act to equalize the negotiation period between small-molecule drugs and biologics under the Drug Price Negotiation Program. Currently, small-molecule drugs and biologics may have different timelines before becoming eligible

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill amends the Social Security Act to equalize the negotiation period between small-molecule drugs and biologics under the Drug Price Negotiation Program. Currently, small-molecule drugs and biologics may have different timelines before becoming eligible for Medicare price negotiation. The bill would align these periods to ensure consistent treatment regardless of drug type. This addresses concerns that the different timelines created unequal incentives for pharmaceutical development between drug categories.

Bill Number: 1492
Sponsor: Gregory F. Murphy (R-NC)
Introduced: 5/19/2025
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means
Policy Area: Economics and Public Finance

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Bill Number: 1492
Sponsor: Gregory F. Murphy (R-NC)
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means
Introduced: 5/19/2025
Summary: This bill amends the Social Security Act to equalize the negotiation period between small-molecule drugs and biologics under the Drug Price Negotiation Program. Currently, small-molecule drugs and biologics may have different timelines before becoming eligible for Medicare price negotiation. The bil

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill amends the Social Security Act to equalize the negotiation period between small-molecule drugs and biologics under the Drug Price Negotiation Program. Currently, small-molecule drugs and biologics may have different timelines before becoming eligible for Medicare price negotiation. The bill would align these periods to ensure consistent treatment regardless of drug type. This addresses concerns that the different timelines created unequal incentives for pharmaceutical development between drug categories.

Last updated: 1/4/2026

Official Summary

Congressional Research Service summary

CBO Show Your Work Act This bill requires the Congressional Budget Office (CBO) to make available to Congress and the public each fiscal model, policy model, and data preparation routine that the CBO uses to estimate the costs and other fiscal, social, or economic effects of legislation. For each estimate of the costs and other fiscal effects of legislation, the CBO must also disclose, in a manner sufficient to permit replication by individuals not employed by the CBO, the data, programs, models, assumptions, and other details of the computations used to prepare the estimate. For data that may not be disclosed, the CBO must make available to Congress and the public <ul> <li> a complete list of all data variables for the data; </li> <li> descriptive statistics for all data variables for the data, to the extent that the descriptive statistics do not violate the rule against disclosure; </li> <li> a reference to the statute requiring that the data not be disclosed; and </li> <li> contact information for the individual or entity who has unrestricted access to the data. </li> </ul>

Key Points

Main provisions of the bill

Equalizes negotiation periods for small-molecule drugs and biologics
Amends Drug Price Negotiation Program under Medicare
Addresses different timeline treatment between drug types
Creates consistent eligibility for price negotiation
Affects pharmaceutical development incentives

How This Impacts Americans

Potential effects on citizens and communities

For pharmaceutical companies: Aligned timelines for both drug types. For Medicare: Consistent negotiation eligibility rules. For small-molecule drug makers: Changed negotiation timeline. For biologic manufacturers: Potentially adjusted timeline. For drug pricing policy: More uniform treatment across categories.

Policy Areas

Primary Policy Area

Economics and Public Finance

Related Subjects

Budget process

Congressional Budget Office (CBO)

Congressional agencies

Congressional oversight

Economic performance and conditions

Government information and archives

Legislative rules and procedure

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

1492, 119th Congress (2025). "To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-1492